{
  "id": 26041,
  "title": "New Drug Prevents Worsening Pulmonary Arterial Hypertension in Major Trial Win",
  "url": "https://urgent.news/2026/07/31/new-drug-prevents-worsening-pulmonary-arterial-hypertension-in-major",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-31T12:53:07.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/cardiology/generalcardiology/122432"
  },
  "original_language": "en",
  "account": "Oral ralinepag demonstrated significant efficacy in preventing the worsening of pulmonary arterial hypertension (PAH), according to a major phase III trial. The study, ADVANCE OUTCOMES, showed that ralinepag reduced the risk of composite first clinical worsening events by half compared to placebo (18% vs 36%; HR 0.45, 95% CI 0.33-0.62). These effects were observed as early as week 8 and persisted through over a year of follow-up. Additionally, ralinepag improved disease progression, initiation of alternative therapies, and long-term clinical responses. However, safety concerns include a higher rate of treatment discontinuations due to adverse events (19%) compared to placebo (3%). The main results were presented at the American Thoracic Society annual meeting, and United Therapeutics plans to submit an FDA approval application based on these findings.",
  "summary": "(MedPage Today) -- Oral ralinepag is positioned for potential FDA approval following its strong results as a treatment for pulmonary arterial hypertension (PAH) in an international phase III trial. In ADVANCE OUTCOMES, ralinepag conferred a reduction...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}